{"id":"W2196580706","doi":"10.1200/jco.2010.28.18_suppl.lba7005","title":"A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19.","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Gefitinib; Internal medicine; Placebo; Lung cancer; Rash; Gastroenterology; Hazard ratio; Epidermal growth factor receptor; Surgery; Cancer; Oncology; Pathology; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005007242,0.0003280309,0.004340505,0.0002454532,0.0001132449,0.00002175134,0.000366362,0.000635457,0.0008083069],"category_scores_gemma":[0.005140983,0.0001836885,0.001568874,0.0003283464,0.0004926254,0.0001469806,0.0000920513,0.002554152,0.000005329845],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003549313,"about_ca_system_score_gemma":0.006604158,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008543939,"about_ca_topic_score_gemma":0.001290533,"domain_scores_codex":[0.9921389,0.001359934,0.005062396,0.0003515222,0.0006207322,0.0004664946],"domain_scores_gemma":[0.9860013,0.007637972,0.004528978,0.0003529864,0.00093565,0.0005431314],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9803993,0.006729422,0.002954127,0.00008255801,0.001294373,0.0001074457,0.0007466001,0.00001639927,0.003516696,0.00004844898,0.001719331,0.00238536],"study_design_scores_gemma":[0.98506,0.006846591,0.001165058,0.0002121033,0.002003605,0.00002927008,0.000123343,0.0003581994,0.001030226,0.00003223841,0.002974829,0.0001644916],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9791389,0.0003389911,0.0001146426,0.005879915,0.006153411,0.006600056,0.00007337106,0.00001209869,0.001688617],"genre_scores_gemma":[0.9932891,0.0003654821,0.0009481311,0.0009171615,0.003042724,0.000366114,0.00001278138,0.00003956743,0.001018938],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0141502,"threshold_uncertainty_score":0.999747,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08185732026370005,"score_gpt":0.4656413726622132,"score_spread":0.3837840523985132,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}